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Abstract
Purpose: To evaluate intensity-modulated radiation therapy (IMRT) as an alternative to conformal
radiotherapy (CRT) or 4-field box boost (4FB) in women with gynecologic malignancies who are
unsuitable for brachytherapy for technical or medical reasons.
Methods: Dosimetric and toxicity information was analyzed for 12 patients with cervical (8),
endometrial (2) or vaginal (2) cancer previously treated with external beam pelvic radiotherapy and
a CRT boost. Optimized IMRT boost treatment plans were then developed for each of the 12
patients and compared to CRT and 4FB plans. The plans were compared in terms of dose
conformality and critical normal tissue avoidance.
Results: The median planning target volume (PTV) was 151 cm3 (range 58–512 cm3). The median
overlap of the contoured rectum with the PTV was 15 (1–56) %, and 11 (4–35) % for the bladder.
Two of the 12 patients, both with large PTVs and large overlap of the contoured rectum and PTV,
developed grade 3 rectal bleeding. The dose conformity was significantly improved with IMRT over
CRT and 4FB (p ≤ 0.001 for both). IMRT also yielded an overall improvement in the rectal and
bladder dose-volume distributions relative to CRT and 4FB. The volume of rectum that received
the highest doses (>66% of the prescription) was reduced by 22% (p < 0.001) with IMRT relative
to 4FB, and the bladder volume was reduced by 19% (p < 0.001). This was at the expense of an
increase in the volume of these organs receiving doses in the lowest range (<33%).
Conclusion: These results indicate that IMRT can improve target coverage and reduce dose to
critical structures in gynecologic patients receiving an external beam radiotherapy boost. This
dosimetric advantage will be integrated with other patient and treatment-specific factors,
particularly internal tumor movement during fractionated radiotherapy, in the context of a future
image-guided radiation therapy study.
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Background
Intra-uterine brachytherapy following external beam radi-
otherapy is an integral component of the treatment of
locally advanced cervix cancer. Patients who are unable to
proceed with brachytherapy because of insufficient tumor
regression during external beam radiotherapy, irregular
pelvic anatomy or concurrent medical problems are at
substantially higher risk of pelvic tumor recurrence [1,2].
It is possible that this largely reflects the intrinsically
worse prognosis of patients with bulky disease at presen-
tation, which regresses poorly in response to external radi-
otherapy. However, it may also reflect the lower total dose
of radiotherapy that can safely be delivered to the tumor
in the absence of brachytherapy. In support of the latter,
several studies have suggested a dose-response relation-
ship for cervix cancer [3-5].
Historically, patients who could not undergo brachyther-
apy received additional external beam radiotherapy deliv-
ered to the gross tumor alone in most radiation centres
around the world, usually using a 4-field box technique
(4FB). The dose of radiotherapy that could be delivered in
this situation was limited by the tolerance of adjacent nor-
mal tissues, including bladder and particularly rectum.
Modern techniques of precision radiation delivery like
intensity-modulated radiation therapy (IMRT) allow the
dose to be "sculpted" to the tumor volume while at the
same time minimizing the dose to adjacent dose-limiting
normal tissues [6,7]. This theoretically offers the opportu-
nity to escalate the tumor dose with the expectation of
improved local control. However, to achieve this goal, the
IMRT boost needs to be delivered in an optimal manner
with close attention to normal tissue dose-volume con-
straints and daily target localization.
The purpose of this study was to: 1) Quantify the potential
advantage of an IMRT boost relative to conventional 4FB
or conformal (CRT) techniques, and 2) Correlate rectal
and bladder toxicity in patients treated using CRT with
dose volume parameters, as a first step in establishing
appropriate normal tissue dose constraints for this popu-
lation.
Methods
Patient characteristics and treatment
Twelve patients with gynecologic cancer who received a
CRT boost in the place of planned brachytherapy after
large field pelvic radiotherapy (PRT) with or without con-
current chemotherapy were retrospectively identified. The
characteristics of the patients are summarized in Table 1.
All tumors were situated in the low central pelvis. There
were eight cervical carcinomas, two vaginal vault carcino-
mas with previous hysterectomy for pre-invasive cervical
disease, one endometrial carcinoma with vaginal vault
recurrence, and one primary serous uterine carcinoma
who had prior subtotal hysterectomy. In seven of the
patients, brachytherapy was judged to be not feasible
based on tumor location and residual disease bulk at the
completion of PRT. In three cases, brachytherapy was
attempted but technically was not feasible. Interstitial
brachytherapy is not routinely practiced in this institution
and hence was not an option for these patients. In the
remaining two patients, brachytherapy was not attempted
because of serious medical co-morbidity.
Table 1: Tumor characteristics and pelvic treatment summary for 12 patients with gynecologic tumors who received a CRT boost
Patient Primary Site FIGO Stage Pelvic 
Technique
Posterior Pelvic 
Attenuator 1
PA RT Pelvic Dose 2 Concurrent 
Chemotherapy 3
1V a g i n a3 P O P N Y 5 0 N
2V a g i n a1 4 F B N N 5 0 Y
3 Cervix 2B 4FB Y N 50 Y
4 Cervix 3B POP N N 50 Y
5 Cervix 2B 4FB N N 45 Y
6 Cervix 2B 4FB Y N 50 Y
7 Cervix 1B 4FB Y N 45 N
8 Cervix 2B 4FB Y N 45 Y
9 Cervix 4A 4FB N N 45 N
10 Uterus 3A 4FB N N 45 Y
11 Uterus Recurrent 4FB N N 45 N
12 Cervix 2B 4FB N N 45 Y
(1) 2 half-value posterior midline attenuator, 3 cm wide at mid-plane
(2) Delivered in 25 fractions over 5 weeks
(3) Cisplatinum 40 mg/m2 weekly for 5 weeks
(FIGO) International Federation of Gynecology and Obstetrics
(PA RT) Para-aortic radiotherapy
(POP) Parallel opposed anterior and posterior fields
(4FB) Four-field box techniqueRadiation Oncology 2006, 1:13 http://www.ro-journal.com/content/1/1/13
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Prior to CRT boost treatment, all patients received external
beam pelvic radiotherapy using either a 4-field technique
or opposed anterior and posterior beams if the primary
tumor was too bulky to spare the posterior pelvis. The pel-
vic dose was 45–50 Gy in 1.8–2 Gy fractions over five
weeks. A two half-value posterior midline attenuator was
used in four patients to reduce the posterior rectal wall
dose by approximately 20%. This is done routinely at our
centre in patients receiving brachytherapy for cervix can-
cer to reduce the risk of serious late rectal morbidity [8].
One patient with gross pelvic lymphadenopathy also
received treatment to para-aortic lymph nodes. Eight
patients received concurrent intravenous chemotherapy
with cisplatinum 40 mg/m2  weekly. The median gap
between PRT and CRT was 11 days (range 1–37 days) with
the median overall treatment days of 63.5 days (range 54–
92 days).
The tumor volumes and adjacent normal organs-at-risk
(OAR) including bladder, rectum and bowel were defined
for each patient by her individual treating physician, using
information from a planning CT scan and pelvic MRI
done after completing PRT specifically for these patients.
The gross tumor volume (GTV) included the high T2 sig-
nal tissues identified using these scans. In general, they
would be the residual tumor within the cervix with its
invasion into the surrounding tissues or the residual vagi-
nal vault tumor. The GTV was expanded 3-dimension-
ally(3D) uniformly by 1 cm and further adjustment by the
individual oncologist based on the clinical history to
define the clinical target volume (CTV), and then by a fur-
ther 0.5 cm (3D) to define the planning target volume
(PTV). This 0.5 cm PTV margin was chosen arbitrarily
based on our departmental set-up error and did not
account for organ motion error which is lacking in pub-
lished literature at the time of this study. The median PTV
was 151 cm3, with a range of 58–512 cm3. The outer
aspect of the rectum was contoured from the level of the
sciatic notch superiorly to the inferior aspect of the obtu-
rator foramen. The entire outer surface of the bladder was
contoured. The median contoured rectal volume was 67
cm3 (range 29–147 cm3), and the median bladder volume
was 183 cm3 (range 49–555 cm3). The PTV overlapped the
contoured rectal and bladder volumes in most patients:
on average 21% (range 1–56%) of the rectal volume was
encompassed by the PTV, as was 13% (range 4–35%) of
the bladder volume. The remaining small and large bowel
was contoured from the level of the L5/S1 junction to the
lower limit of the obturator foramen using the perito-
neum as the surrogate. The median overlap with PTV was
0.98% (range 0–3%) reflecting on the low pelvic position
of the PTV.
The CRT boost plans were optimized to deliver a uniform
dose to the PTV while sparing critical normal tissues.
Between five and eight coplanar 18-MV photon beams
were used as chosen by the physicians and the dosime-
trists at the time of original treatment as the optimal plan.
The prescription dose was at the discretion of the treating
physician and varied between 20 and 30 Gy (median 25.2
Gy) in 1.8–2 Gy daily fractions. Multi-leaf collimators
(MLC) with 1 cm leaves were used to shape the fields to
the beams-eye projections of the PTV. Table 2 summarizes
the CRT as delivered to the patients.
Table 2: Summary of the CRT boost treatment
Structure Parameter All patients Median (Range) Patient 4 Grade 3 Rectal 
Bleeding
Patient 10 Grade 3 Rectal 
Bleeding
Tumor Dose (Gy) 25.2 (20–30) 20 30
PTV (cm3) 151 (58–512) 512 393
CN 0.58 (0.34–0.78) 0.74 0.75
Rectum Volume1 (cm3) 67 (29–147) 61 73
Overlap with PTV2 (%) 15 (1–56) 41 46
V50 (cm3) 57 (22–128) 60 63
V70 (cm3) 45 (16–113) 58 53
Bladder Volume1 (cm3) 183 (49–555) 148 325
Overlap with PTV2 (%) 11 (4–35) 35 20
V50% (cm3) 125 (32–187) 148 161
V70% (cm3) 79 (23–145) 145 106
(1) Rectal and bladder contoured volume before expansion to form the planning risk volume (PRV)
(2) Percentage of the rectum or bladder volume within the PTV
(V50%)The volume receiving ≥ 50% of the prescribed dose
(V70%) The volume receiving ≥ 70% of the prescribed dose
(PTV) Planning target volume
(CN) Conformation Number.Radiation Oncology 2006, 1:13 http://www.ro-journal.com/content/1/1/13
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Patients were followed at 3 monthly intervals for the first
two years after completing radiotherapy, and at six
monthly intervals thereafter. At each visit, the clinical his-
tory was updated and a physical examination, including
pelvic examination, was performed. Laboratory and imag-
ing tests were obtained as required based on clinical find-
ings but an MRI scan was done routinely for these patients
at 6 months post treatment. Late radiation complications
were scored using the RTOG scale for both gastrointestinal
and genitourinary system. The median follow-up was 1.9
years, with a range of 5 months to 3.3 years. This retro-
spective study was approved by the Research Ethics Board
of the University Health Network and Princess Margaret
Hospital.
Comparison of IMRT with CRT and 4FB
Optimized IMRT boost treatment plans were developed
for each of the 12 patients to determine the benefit of
IMRT in this clinical setting. The IMRT plans for each
patient were compared to the CRT plan and to a 4FB tech-
nique, which is historically how patients ineligible for
brachytherapy have been treated in many centres in par-
ticularly those not familiar with interstitial techniques.
The target and normal tissue volumes, as delineated by the
treating physician for each patient, were unaltered for the
purpose of this planning exercise. Rectal and bladder
planning risk volumes (PRVs) for IMRT were defined by
adding a uniform margin of 0.5 and 1 cm respectively to
the contoured organ volumes to assist IMRT dose optimi-
zation.
The 4FB plans were generated by adding a uniform 1 cm
margin to the PTV to account for beam penumbra. MLC
corner shielding was used with a beam energy of 18 MV
for each of the 4-beams.
IMRT planning
Two IMRT boost plans were developed for each patient
using six or eight coplanar beams as shown in Figure 1.
The beam arrangements were chosen to be symmetrical
about the PTV and to avoid treating directly through the
rectum or bladder, which are the major dose limiting
organs. Inverse planning was performed to optimize PTV
dose uniformity (-5 to +7%, ICRU62), and secondarily to
minimize dose to the rectum and bladder [9]. PTV cover-
age was not compromised as a result of overlap with the
rectal and bladder PRVs. The dose-volume constraints for
the portions of the rectum and bladder outside of the PTV
were set so that 30% of the PRV received less than 66% of
the prescribed dose, and 70% of the PRV received less
than 33% of the dose. The IMRT plans were based on a
sliding window method using 6 MV photons to minimize
neutron contamination [10]. All treatment planning was
done with CadPlan/Helios v6.2.7. (Varian Medical Sys-
tems, Inc. Palo Alto, CA).
Treatment plan evaluation
The IMRT treatment plans were compared to the CRT and
4FB plans with respect to PTV coverage and avoidance of
adjacent critical normal tissues. To facilitate this compari-
son of this planning study, a uniform dose of 25.2 Gy was
re-prescribed at the isocenter (the median of the doses
actually delivered to the 12 patients). Cumulative DVHs
were generated for the PTV, contoured rectal volume, and
contoured bladder volume.
The Conformation Number (CN) as described by van't
Riet et al. [11] was used to assess the PTV plan conformity.
Although Feuvret et al. [12] concluded in their review that
the future of conformity indices in everyday practice
remains unclear, we have selected this index as the best
available method in comparing both target coverage as
well as normal tissue avoidance in our data. The CN, in
the context of this analysis, was defined as the product of
the proportion of the PTV encompassed by the 95% isod-
ose volume, and the proportion of the 95% isodose vol-
ume accounted for by the PTV:
CN
PTV encompassed by isodose
PTV
PTV encompassed b
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




        95% y y isodose
isodose volume
 
 
95
95
%
%





 Eq.1
Beam arrangements for the six (a) and eight (b) field IMRT  plans Figure 1
Beam arrangements for the six (a) and eight (b) field IMRT 
plans.Radiation Oncology 2006, 1:13 http://www.ro-journal.com/content/1/1/13
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The first term provides an indication of how well the PTV
is covered by the 95% isodose volume. This was opti-
mized during treatment planning, and was greater than
0.95 for all of the IMRT and CRT plans. The second term
indicates the extent to which the 95% isodose volume
extends beyond the PTV, potentially encompassing adja-
cent OARs. Overall, the CN has a range of possible values
from 0, indicating complete geographic miss of the PTV,
to 1, indicating perfect conformality of the 95% isodose
volume to the PTV.
Normal tissue avoidance was evaluated using the cumula-
tive DVHs for rectum and bladder. Each DVH was divided
into low, intermediate, high and "high-dose tail" regions.
The tissue volumes receiving doses in these four ranges
(VL, VI, VH, VHDT) were derived from the DVH data, as
illustrated in Figure 2. VL  represented those volumes
treated up to 33% of the prescribed dose, while VI, VH, and
VHDT represented the volumes received between 34 to
66%, 67 to 100% and >100% of the prescribed dose,
respectively. VH+VHDT is equivalent to the volume of tissue
receiving greater than 66% of the prescribed dose (V66%),
and VHDT to the volume receiving greater than 100% of the
prescription dose (V100%). This was divided into thirds for
ease of comparison due to the heterogeneity of the origi-
nal prescribed doses.
Results
Clinical outcome after conformal treatment
Nine of 12 patients had complete clinical regression of
disease 12 months after completing CRT. Two patients
had a partial response, and the remaining patient had pro-
gressive pelvic disease and developed distant metastasis.
One of the nine patients who regressed completely
recurred within the high-dose volume 1.8 years later.
Two patients (numbers 4 and 10) developed grade 3 rectal
toxicity with bleeding necessitating intervention. In one
(patient 4) the pelvic tumor was controlled, while the sec-
ond (patient 10) developed central pelvic recurrence 3
months before the onset of rectal bleeding. Both under-
went colonoscopy to establish the diagnosis of late radia-
tion proctitis. As summarized in Tables 1 and 2, both
received PRT with a 4-field technique and concurrent
chemotherapy. The posterior attenuator was not used in
either case at the discretion of the treating physician. Both
had bulky residual disease at the completion of PRT: the
PTVs for these two patients (512 and 393 cm3) were the
largest in the cohort. In addition, the percentage of the
rectal volume that overlapped the PTV was near the high
end of the range in both cases (41% and 46%): only one
patient who did not manifest late rectal toxicity had
greater overlap with the PTV (56%). There was no geni-
tourinary toxicity greater than grade 2 observed.
Comparison of IMRT with CRT and 4FB
Dose conformality and normal tissue avoidance were
used to evaluate the two IMRT beam arrangements. As
shown in Table 3, the CN's for the 6 and 8-field IMRT
plans did not differ significantly, nor did the CN's for the
CRT and 4FB plans. However, the use of IMRT (6 or 8-
fields) significantly improved the conformality relative to
CRT or 4FB treatment (p ≤ 0.001). The 95% isodose line
encompassed 95% or more of the PTV in all of the IMRT
and CRT plans, and in most of the 4FB plans. Therefore,
the improvement in CN with IMRT resulted mainly from
improved conformality of the 95% isodose to the PTV
(second term in Equation 1), with exclusion of adjacent
normal tissues.
Table 4 summarizes the DVHs for the dose-limiting nor-
mal tissues: rectum and bladder. For each IMRT and CRT
plan, ratios were calculated for the volumes of tissue
receiving doses in each of the four previously defined
ranges (VL, VI, VH, VHDT) to the corresponding 4FB vol-
umes in the same patient. A ratio >1 indicates a larger vol-
ume of normal tissue receiving doses in a particular range,
while a ratio <1 indicates relative sparing of normal tissue
in that dose range. This allows evaluation of the relative
benefits of IMRT and CRT in individual patients relative to
4FB treatment, as well as in the entire cohort overall.
Hypothetical cumulative DVH for rectum or bladder Figure 2
Hypothetical cumulative DVH for rectum or bladder. Each 
DVH was divided into low dose (0–33% of the prescription), 
intermediate dose (34–66%), high dose (67–100%), and "high-
dose tail" (>100%) regions. The volume of tissue receiving 
doses in each of these ranges (VL, VI, VH, VHDT) was calcu-
lated.Radiation Oncology 2006, 1:13 http://www.ro-journal.com/content/1/1/13
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As shown in Table 4, both 6-field and 8-field IMRT signif-
icantly reduced the volume of rectum and bladder receiv-
ing high doses >66% of the prescribed dose (VH +VHDT)
relative to 4FB treatment. Six-field IMRT produced a 22%
reduction in the volume of rectum receiving the highest
doses and 19% reduction in the high-dose bladder vol-
ume, compared to reductions of 10% and 22% respec-
tively for 8-field IMRT. There was a trend towards greater
high-dose sparing of the rectum with 6-field IMRT. The
volume of rectum receiving doses in the highest range (VH
+VHDT) was reduced with 6-field IMRT relative to a 4FB
technique in all 12 patients, although the relative reduc-
tion was <5% in three of the patients. These three all had
large PTVs (191–512 cm3) and large overlap of the rectum
with the PTV (28–56% of the contoured rectal volume).
Six-field IMRT produced a median reduction of 9.2 cm3 in
the absolute volume of rectum receiving the highest
doses, with values in individual patients ranging from 0.7
cm3 to 26 cm3. The two IMRT plans resulted in equivalent
high-dose sparing (VH +VHDT) of bladder compared to
CRT or 4FB treatment.
Shown in Table 4, the high-dose sparing with IMRT was
mostly due to a reduction in the volume of tissue receiving
doses between 67% and 100% of the prescribed dose
(VH). Both 6-field and 8-field IMRT resulted in a promi-
nent "high-dose tail" on the rectal and bladder dose-vol-
ume histogram (Figure 2) in some patients,
corresponding to an increased volume of normal tissue
receiving doses above the prescribed dose (VHDT). This
effect was greater with 6-field than with 8-field treatment,
where it tended to offset the dosimetric advantage of
reduced VH. The median increase in rectal VHDT was 110%
with 6-field IMRT relative to 4FB treatment, compared to
a 10% reduction in median VHDT with 8-field IMRT. The
large relative increases in VHDT  seen in some patients
(>100-fold) mainly reflected very small volumes of rec-
tum receiving doses in this range with 4FB treatment. The
median absolute rectal VHDT was 3.2 cm3 (range 0.5–41
cm3) for 6-field IMRT, and 2.6 cm3 (range 0.5–12.7 cm3)
for 8-field treatment. For bladder, the corresponding
numbers were 8.8 cm3 (range 0.3–21 cm3), and 3.7 cm3
(range 0.1–7.9 cm3).
The volume of rectum and bladder receiving doses from 0
to 33% of the prescribed dose (VL) also increased in most
cases with either 6-field or 8-field IMRT relative to a 4FB
technique. The rectal VL increased by a factor of 2.6 (range
1.1–168) with 6-field IMRT, and by a factor of 1.8 (range
0.1–166) with 8-field treatment. Again, the large relative
increases that were seen in some patients largely reflected
the fact that very small volumes of the rectum and bladder
received low doses in this range with the 4FB technique.
The median absolute rectal VL values were 7.9 cm3and 3.4
cm3 respectively with 6- and 8-field IMRT. Similar trends
Table 4: Normal tissue avoidance for the IMRT and CRT plans in 12 patients, Ratio relative to a 4FB technique
Technique OAR Median VL (Range) Median VI (Range) Median VH (Range) Median VHDT (Range) Median VH+VHDT (Range)
IMRT – 6 field Rectum 2.6 (1.1–168) 1.2 (0.4–16.4) 0.7 (0.4–1.5) 2.1 (0–134) 0.781,2 (0.48–0.98)
Bladder 10.7 (1.6–314) 1.0 (0.4–5.1) 0.7 (0.5–0.9) 2.9 (1.0–569) 0.811,2 (0.65–0.98)
IMRT – 8 field Rectum 1.8 (0.1–166) 1.1 (0.6–9.5) 0.9 (0.6–1.5) 0.9 (0.1–208) 0.901,2 (0.61–1.06)
Bladder 7.1 (1.7–490) 1.0 (0.6–8.5) 0.8 (0.6–0.9) 0.8 (0–17) 0.781,2 (0.67–0.88)
CRT Rectum 1.1 (0–71) 1.0 (0.4–12) 1.0 (0.3–1.3) 1.0 (0–1.8) 1.02 (0.61–1.3)
Bladder 7.8 (1.9–336) 0.55 (0.3–0.9) 0.87 (0.4–1.4) 1.1 (0–403) 0.96 (0.85–1.4)
(1) IMRT vs. 4FB, p ≤ 0.001 by t-test
(2) IMRT vs. CRT, p ≤ 0.05
(CRT) Conformal radiotherapy
(IMRT) Intensity-modulated radiotherapy
(4FB) Four field box technique
(VL)Volume of tissue receiving ≤ 33% of the prescription dose
(VI)Volume of tissue receiving 34–66% of the prescription dose
(VH)Volume of tissue receiving 67–100% of the prescription dose
(VHDT)Volume of tissue receiving >100% of the prescription dose (V100%)
(VH+VHDT)Volume of tissue receiving >66% of the prescribed dose (V66%)
Table 3: PTV dose conformality for the IMRT, CRT and 4FB 
plans in 12 patients
Technique CN Median Range CN p
IMRT – 6 field 0.75 0.61–0.87 0.001
IMRT – 8 field 0.75 0.60–0.84 <0.001
CRT 0.6 0.36–0.74 NS
4FB 0.59 0.53–0.62
(4FB) Four field box technique
(CN)Conformation number. A value of zero indicates complete 
geographic miss of the PTV. A value of 1 indicates perfect conformality 
of the 95% isodose volume to the PTV.
(CRT) Conformal radiotherapy
(IMRT) Intensity-modulated radiotherapy
(NS) Not significant
(p) p-value by paired t-test relative to 4FBRadiation Oncology 2006, 1:13 http://www.ro-journal.com/content/1/1/13
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were observed for the bladder, with corresponding
median VL  values of 28.3 cm3  and 10.5 cm3.
Discussion
Ideally, patients with cervix cancer who are candidates for
curative treatment with radiotherapy should receive a
combination of external beam treatment and brachyther-
apy [13,14]. However, in our practice, between 5% and
10% of patients are not candidates for brachytherapy
because of either patient or tumor-specific limitations.
These patients are potential candidates for additional
external beam radiation to the primary tumor, and might
benefit from dose escalation with IMRT. In this study, we
identified a cohort of 12 patients with gynecologic tumors
who were unsuitable for brachytherapy and received a
CRT boost in the pre-IMRT era. Tumor control and toxic-
ity for these patients were correlated with dose-volume
parameters, and the cases were re-planned to assess the
potential benefit of IMRT. The results demonstrate signif-
icant rectal and bladder dose sparing in most patients'
plans. This is the first comparison report of standard frac-
tionation 4FB, CRT, and IMRT in a cohort of this impor-
tant but yet relatively small group of patients who are
unable to undergo brachytherapy, and whose outcome
may be compromised as a result. There is evidence in the
literature that IMRT will improve target coverage and
improve normal tissues sparing for whole pelvic IMRT
[6,7,15,16] as well as a recent study by van de Bunt et al.
[17] that demonstrated repeated IMRT planning as the
tumor shrinks is also advantageous over conventional and
CRT planning for whole pelvic IMRT. One recently pub-
lished report by Mollà et al[18] showed that it is feasible
to use external beam stereotactic radiotherapy using
dynamic-arc or IMRT method as a boost for this popula-
tion of patients. However, unlike this current paper it did
not quantify the degree of improvement that the precision
method can have over a conventional external beam
boost where it is more accessible by all radiation centres
around the world. However, we recognize that to properly
identify dose limitations and toxicity of surrounding nor-
mal tissues, summation of the DVH of PRT and CRT is
needed. However this is beyond the scope of this retro-
spective study where variations existed within the cohort
for both the prescribed dose of PRT and CRT as well as the
deformation of the volumes between these 2 phases of
treatment.
Conformal boost toxicity
As outlined in Table 1 and 2, the treatment received by
these 12 patients was variable in terms of external beam
volume, the use of a posterior attenuator (designed to
limit the rectal external beam dose in the region of highest
brachytherapy dose), the use of concurrent cisplatinum
chemotherapy during external radiation, and the pre-
scribed CRT boost dose and fractionation. These factors,
which all might influence late toxicity, together with the
small number of patients and the relatively short follow-
up particularly for genitourinary side effects [19,20], pre-
vent us from drawing firm conclusions about the relation-
ship between radiotherapy dose-volume parameters and
toxicity. The late complication rate of 17% following CRT
boost treatment that was observed in this series may be
slightly higher than with brachytherapy. By comparison,
we identified a 7.5% rate of grade 3 or 4 complications in
166 patients with cervix cancer who received either LDR
or PDR brachytherapy boost following external radiother-
apy [8]. The two patients in the current series that devel-
oped late rectal bleeding both had large PTVs and large
overlap between the contoured rectal volumes and the
PTV. IMRT, which reduced the volume of rectum receiving
doses in the highest range in most cases, improved the
dose distribution in one of these patients relative to either
CRT or a 4FB approach (VH+VHDT ratios of 0.71 and 0.77
respectively for 6-field IMRT vs. CRT and 4FB, patient 10)
but was of little benefit in the other (VH+VHDT ratios of
0.94 and 0.96 respectively, patient 4). Overall, 6-field
IMRT resulted in potentially significant high-dose rectal
and bladder sparing relative to CRT or 4FB treatment in
nine of 12 patients (VH+VHDT  reduction >10%). This
implies that, while IMRT has the potential to benefit most
Representative axial isodose distributions for six-field IMRT  (a) and conformal (b) treatment plans Figure 3
Representative axial isodose distributions for six-field IMRT 
(a) and conformal (b) treatment plans. The red line is the 
PTV. The yellow line is the 95% isodose.Radiation Oncology 2006, 1:13 http://www.ro-journal.com/content/1/1/13
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patients in this clinical setting, it may be of less value in
those with bulky residual disease in close proximity to rec-
tum or bladder at the completion of large-field pelvic radi-
otherapy.
Our study provides preliminary information about the
relationship between dose-volume parameters and late
radiation complications following external beam boost
treatment for patients with cervix cancer. However, more
accurate and comprehensive data are essential if the
potential of IMRT to expand the therapeutic ratio is to be
maximized in this cohort [21]. Useful data are beginning
to emerge from studies of other pelvic malignancies
treated with high-dose radiotherapy, notably prostate can-
cer [22-25]. In addition, detailed dosimetric studies of
patients receiving brachytherapy for cervix cancer, using
MR-compatible radiation applicators and post-insertion
imaging to generate accurate DVHs for tumor and the crit-
ical OARs [26-30], will provide valuable information in
this regard.
Comparison of IMRT with CRT and 4FB
This study compares IMRT, CRT and 4FB treatment plans
in patients with gynecologic tumors unable to undergo
intracavitary brachytherapy boost, with respect to both
tumor dose conformality and critical normal tissue avoid-
ance. The CN provides an indication of how well the 95%
isodose "hugs" the PTV, and may be superior to the ICRU
Conformity Index [9] to the extent that it also accounts for
the tissue volume outside of the PTV that receives 95% of
the prescription dose or higher [11]. Perfect conformality
will yield a CN of 1.0, while plans where the prescription
isodose extends beyond the PTV will yield values <1.
IMRT produced approximately a 25% (p < 0.001)
improvement in the CN relative to either the CRT or 4FB
techniques (Table 4), which is of potential clinical signif-
icance. There was no difference in the conformality of the
CRT and 4FB plans. This is not surprising given that con-
formal corner shielding with multi-leaf collimators was
used in the 4FB plans, so that these two techniques con-
verge in this respect.
Normal tissue avoidance was assessed using cumulative
DVH's for rectum and bladder, which were divided into
four regions to provide an indication of the volume of tis-
sue receiving doses in the low, intermediate, high and
"high-dose tail" ranges (Figure 2). In most of the patients,
IMRT reduced the volume of rectum and bladder receiving
doses between 67% and 100% of the prescription (VH),
although this was partially offset by an increased volume
of normal tissue receiving doses >100% (VHDT). When
these two volumes were combined (VH + VHDT), a net dosi-
metric advantage of IMRT persisted in most patients: the
volume of rectum that received the highest doses was
reduced by 22% with 6-field IMRT and the volume of
bladder by 19%. This was at the expense of an increase in
the volume of these organs receiving doses in the lowest
range (VL). Table 4 indicates substantial relative increases
in rectal and bladder VL in some patients. However, the
absolute tissue volume receiving doses in the lowest range
was usually small. For example, the median rectal VL was
10.6% (range 1–70%) of the total rectal volume with 6-
field IMRT, 7.3% (range 1–52%) with 8-field IMRT, and
2.7% (range 0–48%) with 4FB radiation. Whether or not
the high-dose sparing advantage of IMRT is offset in some
patients because of an increase in the volume of normal
tissue receiving lower dose resulting higher risk of second-
ary malignancies [31] will need to be addressed in future
larger studies where dose-volume parameters and out-
come are carefully correlated.
An almost infinite number of beam arrangements are the-
oretically possible when developing IMRT treatment tech-
niques. We chose to use a coplanar technique and to
prevent beams from entering or exiting the patient
through the bladder and rectum, which are the major
dose-limiting normal tissues. Therefore, the beams were
arranged laterally and as symmetrically as possible about
the patient and PTV. Two beam arrangements were exam-
ined, one with six fields and the other with eight fields.
Both yielded significant improvement in the CN relative
to CRT or 4FB treatment, and there was no difference
between them in this respect. The 6-field IMRT technique
produced greater rectal sparing in the dose range between
67% and 100% of the prescribed dose (VH) compared to
8-field IMRT, but a more prominent high-dose tail (VHDT).
The net effect when these volumes were combined
(VH+VHDT) suggested a benefit overall for 6-field treat-
ment, as shown in Table 4. With respect to the bladder, 8-
field IMRT yielded greater reduction in both VH and VHDT
relative to 4 FB treatment, and may therefore be preferred
over the 6-field technique. The relative advantages and
disadvantages of these two beam arrangements will likely
vary from patient to patient, and will need to be consid-
ered on an individual basis.
We compared idealized IMRT, CRT and 4FB treatment
plans in patients with gynecologic tumors unable to
undergo brachytherapy boost. It demonstrated a dosimet-
ric advantage to IMRT that should allow dose escalation
and/or a reduction in toxicity relative to other external
beam approaches. However, it did not consider patient
and treatment-related factors that might influence tumor
control or toxicity independent of the boost technique,
such as daily setup variability, internal tumor and organ
movement, tumor regression during radiotherapy, and
the characteristics of the initial large-field pelvic treatment
[21]. Preliminary data from our centre have suggested sig-
nificant movement of the PTV between radiation fractions
in patients with cervix cancer [32], which might increaseRadiation Oncology 2006, 1:13 http://www.ro-journal.com/content/1/1/13
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the risk of geographic miss given the higher dose gradients
associated with IMRT. Daily on-line imaging with com-
pensation for inter-fractional PTV movement may be nec-
essary to overcome this problem, and might enhance the
dosimetric advantage of IMRT even further by allowing
narrower margins around the CTV. This supports the need
for image-guided radiation therapy (IGRT). The use of
concurrent chemotherapy during the initial phase of pel-
vic treatment and extended-field radiotherapy to encom-
pass para-aortic lymph nodes may both increase the risk
of radiation complications [33-36], which underscore the
importance of integrating all aspects of treatment in indi-
vidual patients so as to maximize outcome.
Conclusion
This study demonstrates that conformal external beam
radiotherapy can safely be delivered as a boost to the
residual tumor in patients with gynecologic cancers who
are unsuitable for brachytherapy. IMRT produces
improved PTV conformality and high-dose sparing of rec-
tum and bladder relative to CRT or 4FB treatment, and
should allow dose escalation with the expectation of
improved outcome. This information will need to be care-
fully integrated with other patient and treatment-specific
factors, particularly documentation of internal tumor
movement during fractionated radiotherapy in terms of
online IGRT, to assure optimal patient outcome.
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